suck pdf from google scholar
unlimited free pdf from europmc19475783    free
PDF from PMC    free
html from PMC    free
PDF vom PMID19475783 :   free
PDF vom PMID19475783 :   free
suck pdf from library genesis
English Wikipedia

Nephropedia Template TP (

Twit Text

  • DeepDyve
  • Pubget Overpricing

  • lüll
  • Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel
  • Motovska Z; Widimsky P
  • Vasc Health Risk Manag 2009[]; 5 (1): 475-81
  • Dual oral antiplatelet therapy, aspirin plus thienopyridine, has permitted a rapid increase in the use of coronary intervention procedures. Clopidogrel is the thienopyridine of choice for dual antiplatelet therapy in patients treated with percutaneous coronary intervention. However, there are two issues with clopidogrel: (1) clopidogrel's antiplatelet activity is delayed because the drug needs to be metabolized into its active form and (2) variability in patient response to clopidogrel has been demonstrated. To overcome these shortcomings of clopidogrel, new more potent inhibitors of P2Y12 receptors, which have a more rapid onset of action have been introduced for clinical evaluation. This article is a nonexhaustive review of the literature and concentrates on prasugrel, a third-generation, oral thienopyridine. The purpose is to summarize the current knowledge about the benefits and risks of prasugrel and to outline the most prudent strategies for the drug's clinical use.
  • |Administration, Oral[MESH]
  • |Angioplasty, Balloon, Coronary/*adverse effects/instrumentation[MESH]
  • |Aspirin/therapeutic use[MESH]
  • |Clopidogrel[MESH]
  • |Coronary Thrombosis/etiology/*prevention & control[MESH]
  • |Diabetes Complications/therapy[MESH]
  • |Drug Resistance/genetics[MESH]
  • |Drug Therapy, Combination[MESH]
  • |Humans[MESH]
  • |Myocardial Infarction/*therapy[MESH]
  • |Piperazines/administration & dosage/adverse effects/*therapeutic use[MESH]
  • |Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*therapeutic use[MESH]
  • |Prasugrel Hydrochloride[MESH]
  • |Risk Assessment[MESH]
  • |Risk Factors[MESH]
  • |Stents[MESH]
  • |Thiophenes/administration & dosage/adverse effects/*therapeutic use[MESH]
  • |Ticlopidine/analogs & derivatives/therapeutic use[MESH]
  • |Treatment Outcome[MESH]

  • *{{pmid19475783}}
    *<b>[ Improving outcomes in patients undergoing percutaneous coronary intervention: role of prasugrel ]</b> Vasc Health Risk Manag 2009; 5(1) ; 475-81 Motovska Z; Widimsky P


    Nephropedia PMID record

    Deutsche Wikipedia - im Artikel

    Hier den unten stehenden Textblock hineinkopieren

    Vasc Health Risk Manag

    475 1.5 2009